Bg pattern

ZIMBUS BREEZHALER 114/46/136 micrograms INHALATION POWDER (HARD CAPSULE)

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use ZIMBUS BREEZHALER 114/46/136 micrograms INHALATION POWDER (HARD CAPSULE)

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the User

Zimbus Breezhaler 114micrograms/46micrograms/136microgramspowder for inhalation (hard capsule)

indacaterol/glycopyrronium/mometasone furoate

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again. If you have any further questions, ask your doctor, pharmacist, or nurse.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

  1. What Zimbus Breezhaler is and what it is used for
  2. What you need to know before you use Zimbus Breezhaler
  3. How to use Zimbus Breezhaler
  4. Possible side effects
  5. Storing Zimbus Breezhaler
  6. Contents of the pack and further information

Instructions for using the Zimbus Breezhaler inhaler

1. What Zimbus Breezhaler is and what it is used for

What Zimbus Breezhaler is and how it works

Zimbus Breezhaler contains three active substances:

  • indacaterol
  • glycopyrronium
  • mometasone furoate

Indacaterol and glycopyrronium belong to a group of medicines called bronchodilators. They work in different ways to relax the muscles of the small airways in the lungs. This helps to open up the airways and makes it easier to breathe in and out. When used regularly, they help the small airways in the lungs to stay open.

Mometasone furoate belongs to a group of medicines called corticosteroids (or steroids). Corticosteroids reduce the swelling and irritation (inflammation) of the small airways in the lungs and in this way gradually relieve breathing problems. Corticosteroids also help to prevent asthma attacks.

What Zimbus Breezhaler is used for

Zimbus Breezhaler is used as a regular treatment for asthma in adults.

Asthma is a serious, chronic lung disease in which the muscles around the smaller airways tighten (bronchoconstriction) and become inflamed. The symptoms come and go and include difficulty breathing, wheezing, chest tightness, and coughing.

You should use Zimbus Breezhaler every day as directed by your doctor and not just when you have breathing problems or other symptoms of asthma. This will ensure that your asthma is adequately controlled. Do not use this medicine to relieve a sudden attack of shortness of breath or wheezing.

Ask your doctor if you have any questions about how Zimbus Breezhaler works or why you have been prescribed this medicine.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you use Zimbus Breezhaler

Follow your doctor's instructions carefully.

Do not use Zimbus Breezhaler

  • if you are allergic to indacaterol, glycopyrronium, mometasone furoate, or any of the other ingredients of this medicine (listed in section 6). If you think you may be allergic, consult your doctor.

Warnings and precautions

Talk to your doctor, pharmacist, or nurse beforeusing Zimbus Breezhaler if any of the following apply to you:

  • if you have heart problems, including a fast or irregular heartbeat,
  • if you have thyroid problems,
  • if you have been told you have diabetes or high blood sugar levels,
  • if you have seizures or fits,
  • if you have severe kidney problems,
  • if you have severe liver problems,
  • if you have low potassium levels in your blood,
  • if you have a condition called narrow-angle glaucoma,
  • if you have difficulty urinating,
  • if you have pulmonary tuberculosis (TB)or any other long-standing or untreated infection.

During treatment with Zimbus Breezhaler

Stop using this medicine and seek medical help immediatelyif you experience any of the following:

  • chest tightness, cough, wheezing, or difficulty breathing immediately after using Zimbus Breezhaler (signs that the medicine unexpectedly tightens the airways, known as paradoxical bronchospasm),
  • difficulty breathing or swallowing, swelling of the tongue, lips, or face, skin rash, itching, and hives (signs of an allergic reaction),
  • eye pain or discomfort, blurred vision, halos, or colored images around lights (signs of an acute attack of narrow-angle glaucoma).

Children and adolescents

Do not give this medicine to children or adolescents (under 18 years of age) because it has not been studied in this age group.

Other medicines and Zimbus Breezhaler

Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines. In particular, tell your doctor or pharmacist if you are using:

  • medicines that lower the amount of potassium in the blood. These include diuretics (which increase urine production and may be used to treat high blood pressure, e.g., hydrochlorothiazide), other bronchodilators such as methylxanthines used for respiratory disorders (e.g., theophylline), or corticosteroids (e.g., prednisolone).
  • tricyclic antidepressants or monoamine oxidase inhibitors (medicines used to treat depression).
  • any medicine that may be similar to Zimbus Breezhaler (containing similar active substances); as their combined use may increase the risk of side effects.
  • beta-blocker medicines that may be used for high blood pressure or other heart problems (such as propranolol), or to treat glaucoma (e.g., timolol).
  • ketoconazole or itraconazole (medicines used to treat fungal infections).
  • ritonavir, nelfinavir, or cobicistat (medicines used to treat HIV infection).

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before using this medicine. Your doctor will decide whether you can use Zimbus Breezhaler.

Driving and using machines

Zimbus Breezhaler is unlikely to affect your ability to drive or use machines.

Zimbus Breezhaler contains lactose

This medicine contains approximately 25 mg of lactose per capsule. If your doctor has told you that you have an intolerance to some sugars, consult them before taking this medicine.

3. How to use Zimbus Breezhaler

Follow the instructions for using this medicine exactly as your doctor or pharmacist has told you. If you are unsure, ask your doctor or pharmacist again.

How much Zimbus Breezhaler to inhale

The usual dose is to inhale the contents of one capsule each day. You only need to inhale the medicine once a day. Do not use more doses than your doctor has prescribed.

You should use Zimbus Breezhaler every day, even if you do not feel unwell due to your asthma.

When to inhale Zimbus Breezhaler

Inhale Zimbus Breezhaler at the same time each day. This will help you control your symptoms throughout the day and night. It will also help you remember to use it.

How to inhale Zimbus Breezhaler

  • Zimbus Breezhaler is for inhalation use only.
  • In this pack, you will find an inhaler and capsules that contain the medicine. The inhaler allows you to inhale the medicine in the capsule. Use the capsules only with the inhaler provided in this pack. The capsules should be kept in the blister pack until you need to use them.
  • Peel off the foil to open the blister pack, do not push the capsule through the foil.
  • When starting a new pack, use the new inhaler provided in the pack.
  • Discard the inhaler from each pack once you have used all the capsules.
  • Do not swallow the capsules.
  • For more information on how to use the inhaler, please read the instructions at the end of this leaflet.

If your pack contains a sensor for Zimbus Breezhaler

  • The sensor and the app are not needed for you to take your medicine. The sensor does not need to be connected to the app when you use your medicine.
  • Your doctor will decide if using the sensor and the app is right for you.
  • The electronic sensor for Zimbus Breezhaler attaches to the base of the Zimbus Breezhaler inhaler.
  • The sensor confirms that you have used the Zimbus Breezhaler inhaler by recording and monitoring the actions and noise made by the capsule when it is turned during inhalation, but it does not monitor whether you have received your dose of medicine.
  • The sensor must be used with the Propeller app on your mobile phone or any other suitable device. The sensor connects to the Propeller app via Bluetooth.
  • For more information on how to use the sensor for Zimbus Breezhaler and the app, please read the instructions for use provided with the pack containing the sensor and the app.
  • Once you have used all the Zimbus Breezhaler capsules from one pack, transfer the sensor to the new inhaler in the next pack of Zimbus Breezhaler.

If your symptoms do not improve

If your asthma does not improve or even gets worse after you have started using Zimbus Breezhaler, talk to your doctor.

If you use more Zimbus Breezhaler than you should

If you accidentally inhale too much of this medicine, contact your doctor or hospital immediately. Medical attention may be needed.

If you forget to use Zimbus Breezhaler

If you miss a dose at the usual time, inhale it as soon as you can on that day. Then, the next day, inhale the next dose at the usual time. Do not inhale two doses on the same day.

If you stop using Zimbus Breezhaler

Do not stop using Zimbus Breezhaler unless your doctor tells you to. Your asthma symptoms may come back if you stop using it.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Some side effects may be serious

Stop using Zimbus Breezhaler and seek medical help immediately if you experience any of the following:

Common:may affect up to 1 in 10 people

  • difficulty breathing or swallowing, swelling of the tongue, lips, or face, skin rash, itching, and hives (signs of an allergic reaction).

Other side effects

The following are other side effects. If these side effects begin to be severe, please talk to your doctor, pharmacist, or nurse.

Very common:may affect more than 1 in 10 people

  • sore throat
  • nasal discharge
  • sudden difficulty breathing and feeling of chest tightness with wheezing or coughing

Common:may affect up to 1 in 10 people

  • mouth thrush (signs of candidiasis). After you have inhaled your dose, rinse your mouth with water or a mouthwash and spit. This will help prevent thrush.
  • frequent urination and pain or burning when urinating (signs of urinary tract infection)
  • headache
  • fast heartbeat
  • cough
  • hoarseness
  • diarrhea, abdominal cramps, nausea, and vomiting (gastroenteritis)
  • muscle, bone, or joint pain (signs of musculoskeletal pain)
  • muscle spasms
  • fever

Uncommon:may affect up to 1 in 100 people

  • dry mouth
  • skin rash
  • high blood sugar levels
  • itching
  • difficulty and pain when urinating (signs of dysuria)
  • clouding of the lenses in your eyes (signs of cataract)

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storing Zimbus Breezhaler

  • Keep this medicine out of the sight and reach of children.
  • Do not use this medicine after the expiry date which is stated on the carton and blister after ‘EXP’. The expiry date refers to the last day of that month.
  • Do not store above 30°C.
  • Store the capsules in the original blister pack to protect them from light and moisture and do not remove them until just before use.
  • Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
  • If your pack contains an electronic sensor for Zimbus Breezhaler, please consult the instructions for use provided with the pack containing the sensor for detailed instructions on how to store it and when to discard it.

6. Package Contents and Additional Information

Zimbus Breezhaler Composition

  • The active ingredients are indacaterol (as acetate), glycopyrronium (as bromide), and mometasone furoate. Each capsule contains 150 micrograms of indacaterol (as acetate), 63 micrograms of glycopyrronium bromide (equivalent to 50 micrograms of glycopyrronium), and 160 micrograms of mometasone furoate. Each delivered dose (the dose delivered by the inhaler mouthpiece) contains 114 micrograms of indacaterol (as acetate), 58 micrograms of glycopyrronium bromide (equivalent to 46 micrograms of glycopyrronium), and 136 micrograms of mometasone furoate.
  • The other ingredients are lactose monohydrate and magnesium stearate (see the section "Zimbus Breezhaler contains lactose" in section 2).

Product Appearance and Package Contents

In this package, you will find an inhaler along with capsules in blisters. Some packages also contain a sensor. The capsules are transparent and contain a white powder. They have the product code "IGM150-50-160" printed in black above two black bars on the body and with the product logo printed in black and surrounded by a black bar on the cap.

The following package sizes are available:

Single pack containing 10 x 1, 30 x 1, or 90 x 1 hard capsules, along with 1 inhaler.

Package containing 30 x 1 hard capsules, along with 1 inhaler and 1 sensor.

Multiple packs containing 15 boxes, each with 10 x 1 capsules along with 1 inhaler.

Only some package sizes may be marketed.

Marketing Authorization Holder

Novartis Europharm Limited

Vista Building

Elm Park, Merrion Road

Dublin 4

Ireland

Manufacturer

Novartis Farmacéutica, S.A.

Gran Via de les Corts Catalanes, 764

08013 Barcelona

Spain

Novartis Pharma GmbH

Roonstraße 25

D-90429 Nuremberg

Germany

Novartis Pharma GmbH

Sophie-Germain-Strasse 10

90443 Nuremberg

Germany

You can request more information about this medicinal product by contacting the local representative of the marketing authorization holder:

België/Belgique/Belgien

Novartis Pharma N.V.

Tél/Tel: +32 2 246 16 11

Lietuva

SIA Novartis Baltics Lietuvos filialas

Tel: +370 5 269 16 50

Text in Bulgarian language with the name Novartis Bulgaria Eood and phone number +359 2 489 98 28

Luxembourg/Luxemburg

Novartis Pharma N.V.

Tél/Tel: +32 2 246 16 11

Ceská republika

Novartis s.r.o.

Tel: +420 225 775 111

Magyarország

Novartis Hungária Kft.

Tel.: +36 1 457 65 00

Danmark

Novartis Healthcare A/S

Tlf: +45 39 16 84 00

Malta

Novartis Pharma Services Inc.

Tel: +356 2122 2872

Deutschland

Novartis Pharma GmbH

Tel: +49 911 273 0

Nederland

Novartis Pharma B.V.

Tel: +31 88 04 52 111

Eesti

SIA Novartis Baltics Eesti filiaal

Tel: +372 66 30 810

Norge

Novartis Norge AS

Tlf: +47 23 05 20 00

Ελλάδα

Novartis (Hellas) A.E.B.E.

Τηλ: +30 210 281 17 12

Österreich

Novartis Pharma GmbH

Tel: +43 1 86 6570

España

Laboratorios Gebro Pharma, S.A.

Tel: +34 93 205 86 86

Polska

Novartis Poland Sp. z o.o.

Tel.: +48 22 375 4888

France

Novartis Pharma S.A.S.

Tél: +33 1 55 47 66 00

Portugal

Laboratório Medinfar - Produtos Farmacêuticos, S.A.

Tel: +351 21 499 7400

Hrvatska

Novartis Hrvatska d.o.o.

Tel. +385 1 6274 220

România

Novartis Pharma Services Romania SRL

Tel: +40 21 31299 01

Ireland

Novartis Ireland Limited

Tel: +353 1 260 12 55

Slovenija

Novartis Pharma Services Inc.

Tel: +386 1 300 75 50

Ísland

Vistor hf.

Sími: +354 535 7000

Slovenská republika

Novartis Slovakia s.r.o.

Tel: +421 2 5542 5439

Italia

Novartis Farma S.p.A.

Tel: +39 02 96 54 1

Suomi/Finland

Novartis Finland Oy

Puh/Tel: +358 (0)10 6133 200

Κύπρος

Novartis Pharma Services Inc.

Τηλ: +357 22 690 690

Sverige

Novartis Sverige AB

Tel: +46 8 732 32 00

Latvija

SIA Novartis Baltics

Tel: +371 67 887 070

United Kingdom (Northern Ireland)

Novartis Ireland Limited

Tel: +44 1276 698370

Date of Last Revision of this Leaflet:

Other Sources of Information

Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu.

Zimbus Breezhaler Inhaler Instructions for Use

Please read the complete Instructions for Use of the Zimbus Breezhaler inhaler before using it.

Inhaler with arrows showing steps of use: insert, pierce and release, inhale deeply and check empty capsule

Sequence of steps to use a capsule inhaler showing opening, piercing, inhalation, and verification of correct use

Removal of capsule from blister, inhaler with mouthpiece, face holding breath and rinsing mouth with water

Online doctors for ZIMBUS BREEZHALER 114/46/136 micrograms INHALATION POWDER (HARD CAPSULE)

Discuss questions about ZIMBUS BREEZHALER 114/46/136 micrograms INHALATION POWDER (HARD CAPSULE), including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
5.0 (17)
Doctor

Anastasiia Shalko

Family medicine 13 years exp.

Dr. Anastasiia Shalko is a general practitioner with a background in both paediatrics and general medicine. She graduated from Bogomolets National Medical University in Kyiv and completed her paediatric internship at the P.L. Shupyk National Medical Academy of Postgraduate Education. After working as a paediatrician in Kyiv, she relocated to Spain, where she has been practising general medicine since 2015, providing care for both adults and children.

Her work focuses on urgent, short-term medical concerns – situations where patients need quick guidance, symptom assessment and clear next steps. She helps people understand whether their symptoms require in-person evaluation, home management or a change in treatment. Common reasons for booking an online consultation include:

  • acute respiratory symptoms (cough, sore throat, runny nose, fever)
  • viral illnesses such as colds and seasonal infections
  • gastrointestinal complaints (nausea, diarrhoea, abdominal pain, gastroenteritis)
  • sudden changes in how a child or adult feels
  • questions about existing treatment and whether adjustments are needed
  • renewal of prescriptions when clinically appropriate
Dr. Shalko works specifically with urgent and short-term problems, providing practical recommendations and helping patients determine the safest next step. She explains symptoms clearly, guides patients through decision-making and offers straightforward medical advice for everyday acute issues.

She does not provide long-term management of chronic conditions, ongoing follow-up or comprehensive care plans for complex long-term illnesses. Her consultations are designed for acute symptoms, sudden concerns and situations where timely medical input is important.

With clinical experience in both paediatrics and general medicine, Dr. Shalko confidently supports adults and children. Her communication style is clear, simple and reassuring, helping patients feel informed and supported throughout the consultation.

Camera Book a video appointment
€50
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80

Frequently Asked Questions

Is a prescription required for ZIMBUS BREEZHALER 114/46/136 micrograms INHALATION POWDER (HARD CAPSULE)?
ZIMBUS BREEZHALER 114/46/136 micrograms INHALATION POWDER (HARD CAPSULE) requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in ZIMBUS BREEZHALER 114/46/136 micrograms INHALATION POWDER (HARD CAPSULE)?
The active ingredient in ZIMBUS BREEZHALER 114/46/136 micrograms INHALATION POWDER (HARD CAPSULE) is indacaterol, glycopyrronium bromide and mometasone. This information helps identify medicines with the same composition but different brand names.
How much does ZIMBUS BREEZHALER 114/46/136 micrograms INHALATION POWDER (HARD CAPSULE) cost in pharmacies?
The average pharmacy price for ZIMBUS BREEZHALER 114/46/136 micrograms INHALATION POWDER (HARD CAPSULE) is around 72.68 EUR. Prices may vary depending on the manufacturer and dosage form.
Who manufactures ZIMBUS BREEZHALER 114/46/136 micrograms INHALATION POWDER (HARD CAPSULE)?
ZIMBUS BREEZHALER 114/46/136 micrograms INHALATION POWDER (HARD CAPSULE) is manufactured by Novartis Europharm Limited. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of ZIMBUS BREEZHALER 114/46/136 micrograms INHALATION POWDER (HARD CAPSULE) online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether ZIMBUS BREEZHALER 114/46/136 micrograms INHALATION POWDER (HARD CAPSULE) is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to ZIMBUS BREEZHALER 114/46/136 micrograms INHALATION POWDER (HARD CAPSULE)?
Other medicines with the same active substance (indacaterol, glycopyrronium bromide and mometasone) include ENERZAIR BREEZHALER 114 mcg/46 mcg/136 mcg inhalation powder (hard capsule), ANORO ELLIPTA 55 MCG/22 MCG INHALATION POWDER (SINGLE-DOSE), BRIMICA GENUAIR 340/12 micrograms powder for inhalation. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media